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Background: Studies from low-income countries report positive non-specific effects of early
Bacillus Calmette-Guérin (BCG) immunisation on childhood health and survival. Neonatal
immunisation with BCG may prime the immune system and offer partial protection against
other infectious and possibly allergic diseases. The potential clinical value of these non-
specific effects has not yet been examined in a large randomised trial in high-income
countries.
Methods: TheDanish Calmette Study is amulticentre randomised clinical trial conducted between
October 2012 and November 2015. Within the first 7 days of life, infants were randomly assigned
to intra-dermal vaccination with BCG or no intervention. At 3 and 13 months of age structured
telephone interviews and clinical examinations of the children were conducted. In a subgroup of
children blood samples were drawn and stool samples collected at age 4 days, 3 and 13 months.
Thymus index was assessed by ultrasound in a subgroup at randomisation and at 3 months. The
primary study outcome is hospitalisation within the first 15 months of life as assessed in Danish
health registers. Secondary outcomes include infectious disease hospitalisations, wheezing, eczema,
use of prescribed medication, growth, development, thymus index, T- and B-cell subpopulations
assessed by flow cytometry, in vitro cytokine responses and specific antibody responses to other
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Discussion:With participation of 4184 families andmore than 93% adherence to clinical follow-up
at 3 and 13 months, this randomised clinical trial has the potential to create evidence regarding
non-specific effects of BCG vaccination in a high-income setting.
© 2015 The Authors. PublishedbyElsevier Inc.This isanopenaccessarticleunder theCCBY-NC-NDlicense
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The Bacillus Calmette-Guérin vaccine (BCG) is administered
to infants in more than 100 countries to protect against the
most severe forms of tuberculosis [1]. Due to a declining in-
cidence of tuberculosis, BCG was withdrawn from the Danish
Childhood Immunisation Program in the 1980s.
Many observational studies from low-income settings have
reported positive non-specific effects of neonatal BCG im-
munisation on childhood health and survival [2–5]. One study
fromWest Africa found reduced sensitisation to allergens among
BCG-immunised children [5]. Recently, two randomised trials
among low-birth-weight children observed a significantly lower
mortality in the group BCG-immunised at birth than those who
received the usual delayed BCG [6,7]. Morbidity and mortality
due to infectious diseases in early infancy are high inWest Africa
while tuberculosis is very uncommon in infancy. Therefore, a
protective mechanism has to be non-specific.
During the past three decades eczema and asthma have
become the most common chronic diseases among children in
high-income countries [8]. Research suggests that a skewed
immunologic stimulation, possibly caused by increased hy-
giene and fewer infections, may be part of the explanation for
the increased prevalence of these diseases [9]. BCG strongly
stimulates the immune system, resulting in an interferon
gamma (IFN-γ) response [10] that may counterbalance the T-
helper-cell (Th)-2 response found in atopic individuals. It has
therefore been hypothesised that BCG could have a protective
effect on atopic diseases, but results from several retrospective
studies have been inconsistent [11–14]. According to a meta-
analysis from 2014 BCG vaccination might have exerted a
protective effect against non-atopic asthma, although it did not
protect against allergic sensitisation [15]. Apart from a small
randomised trial from the Netherlands [16], no randomised
trials of BCG's effect on allergic diseases have been conducted.
The Dutch trial found significantly reduced use of medication
for eczema among the BCG-immunised children [16].
In the present trial we aimed to test the effect of BCG on
hospitalisation and morbidity including allergic diseases in
high-income settings in a large clinical trial with patient-
relevant outcomes. Our main hypothesis was that neonatal
BCG vaccination would be associated with a 20% reduction
in hospitalisation during the first 15 months of life.
2. Methods/design
The Danish Calmette Study is a multicentre randomised
clinical trial with 1:1 allocation of newborns within 7 days
of birth to either BCG vaccination or no intervention. The
inclusion criteria were gestational age of at least 32 weeks, a
birth weight of at least 1000 g, and a signed consent form from
the parents. Exclusion criteria were maternal intake of immune
modulatingmedicine during pregnancy or signs of severe illness
or major malformation in the newborn. Only parents fluent in
Danish were included, as questionnaires in Danish were used.
3. Setting
FromOctober 2012 toNovember 2013 all parents planning to
give birth at Rigshospitalet, Hvidovre Hospital, and Kolding
Hospital received a letter in the 2nd or 3rd trimester of
pregnancy with information about the Danish Calmette Study
and an invitation to participate in the study. Invited parentswere
contacted byphone andoffered further information either on the
phone or, on request, at a personal meeting.We obtained ethical
permission to inform the women by phone.
4. Interventions
Within 7 days of birth participants were randomised to
either the intervention group (BCG immunisation) or to the
control group using an electronic case report form (e-crf).
Randomisation was stratified by sex, hospital and gestational
age (≥37 weeks of gestation versus b37 weeks). Block sizes
were 2–4–6 in randomorder. Twins and triplets were allocated
to the same randomisation group based on the sex of the first
born child. The random allocation sequence was generated by
the e-crf shortly before the vaccination andwas concealed to all
study staff until the intervention was assigned. Specially
trained midwives and study health professionals at the three
trial sites assigned participants to intervention and vaccinated
children in the BCG group intra-dermally with BCG vaccine,
SSI strain 1331, in the standard dose of 0.05 ml in the upper,
lateral part of the left shoulder. The children randomised to
the control group were not given a placebo vaccine and the
parents were not blinded to the intervention because no
other injection can mimic the typical reaction following a
BCG vaccination.
The English product summary of BCG from SSI can
be found on the website http://www.immune.org.nz/sites/
default/files/resources/
SSI%20BCG%20vaccine%20data%20sheet.pdf.
Before randomisation of their child the parents received
written and oral information about the most common adverse
reactions after BCG vaccination (Table 1).
Table 1




Local: Enlargement of regional lymph node
N1 cm. Ulceration with a discharging ulcer at the
site of injection.
Rare (b1/1000) Systemic: Disseminated BCG complications as
osteitis or osteomyelitis. Allergic reactions,
including anaphylactic reactions.
Local: Suppurative lymphadenitis, abscess
formation.
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In case of suspected adverse reactions other than the
expected redness, swelling, skin sore, swollen regional lymph
nodes and a scar, the parents were instructed to contact the
study staff as soon as possible, so the case could be reported and
medical advice be given and, if needed, the child referred to
clinical control and treatment. The Data Safety and Monitoring
Board (DSMB) of the Danish Calmette Study regularly evaluated
the patterns of adverse reactions.
5. Outcomes
The primary outcome of the Danish Calmette Study is
hospitalisation in the first 15 months of life. The secondary
outcomes include infectious disease hospitalisations, atopic
dermatitis, asthmatic bronchitis, use of prescribed medication,
development, anthropometrics measured at 3 and 13 months,
immunological outcomes (T- and B-cell subpopulations assessed
by flow cytometry and cytokine production in stimulated whole
blood) measured at 4 days of age, 3 and 13 months and thymus
volume as measured by ultrasound scanning (thymus index)
and the ratio between thymus volume and infant body weight
(thymus/weight index) measured at inclusion and at 3 months.
We also investigated which factors affect parents' decision
concerning participation in the Danish Calmette Study and
whether their experience with the BCG vaccination influenced
their attitude towards future vaccinations.
6. Data collection
6.1. Background information
A structured telephone interview was conducted prior to
randomisation focusing on demographics and risk factors such
as atopic disposition and parental smoking habits. All tele-
phone interviews, including the later mentioned follow-up
interviews, were performed by specially trained study staff. All
members of the study staff had a medical background as either
doctors, nurses, midwives, medical students or midwife
students.
6.2. Registry-based data
Hospitalisations were identified using the Danish National
Patient Registry [17]. All Danish citizens have a unique social
security number (CPR) that can be used to link data at an
individual level. The Danish Register of Medicinal Product
Statistics contains CPR-number-based information about sale
of all prescribed medicines in Denmark. The included children
were followed in these registries until 15 months of age for
hospitalisations, total medication use, including use of
antibiotics, anti-asthmatics, and topical medication against
eczema.
6.3. Clinical and paraclinical data
6.3.1. At inclusion
Thymic scans: At the time of randomisation, just before
vaccination, thymus index (a volume estimate) and thymus/
weight index (the ratio between thymus volume and infant
body weight) were assessed using a transsternal ultrasonic
method [18] on a subpopulation of 300 children (thymus
cohort), including the 150 children who delivered a blood
sample (see below).
6.3.2. 4-day follow-up
Blood samples: At Hvidovre Hospital blood samples were
obtained from 150 children (blood sample cohort), 75 children
from each randomisation group, 4 days after randomisation.
The samples were used for immunological analyses, includ-
ing total leukocyte count, assessment of T- and B-cell
subpopulations (recent thymic emigrants, naive cells, cen-
tral memory cells, effector memory cells, late differentiated
cells, Th17 cells, Tc17 cells, regulatory B-cells, regulatory
T-cells, chronic activated cells, apoptic cells) measured by six-
colour flow cytometry in whole blood and examination of the
production of cytokines (tumor necrosis factor (TNF)-α,
interleukin (IL)-1β, IL-6, IFN-γ, IL-10, IL-17, IL-22) using whole
blood stimulated in vitro with other pathogens, RPMI (medium
alone), lipopolysaccharide (LPS), phytohaemagglutanin (PHA),
Escherichia coli (E. coli), Streptococcus pneumonia (S. pneu),
Candida albicans (C. alb), and BCG. Stool samples for microbiome
analyseswere obtained froma subset of participants in the blood
sample cohort.
6.3.3. 3-month follow-up
Structured telephone interviews were conducted at age
3 months to obtain parent-reported data on illness episodes,
vaccinations, anthropometrics and nutrition. At the end of the
telephone interview the e-crf revealed a few supplementary
questions to parents of the BCG-vaccinated children about the
reaction at the vaccination site and the information received
about adverse reactions. All children were invited for a clinical
examination at the study facility.
The clinical examination was conducted by specially
trained study staff (doctors and nurses) and included:
anthropometrics (weight, height and head circumference),
heart and lung auscultation, and examination for eczema
and wheeze. In case of atopic dermatitis, the Scoring Atopic
Dermatitis (SCORAD) form was used [19]. Parents were
instructed not to reveal the randomisation group of their
child when interviewed on the phone and when they attended
the clinical examination. Before performing the clinical exami-
nation we asked the parents to cover the typical site of
vaccination using a plaster. At Hvidovre Hospital blood
samples were drawn from the blood sample cohort and the
immunological analyses were repeated. Stool samples were
obtained from a subset of participants in the blood sample
cohort and thymus index and thymus/weight index were
assessed in the thymus cohort.
6.3.4. 13-month follow-up
The structured telephone interview from the 3-month
follow-up was repeated, supplemented with questions con-
cerning the use of healthcare services. To measure the
children's psychomotor development, their parents were
asked to fill out a standardised, validated online Ages and
Stages Questionnaire (ASQ) [20]. The children were invited
for a clinical examination.
The clinical examination assessed the same outcomes as at
3 months of age, supplemented with measuring of skin folds,
abdominal circumference and mid upper arm circumference
(MUAC). At the very end of the last clinical examination the
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length and width of the BCG scar was measured after the
parents had removed the plaster.
At Hvidovre Hospital blood samples were drawn from
the blood sample cohort and in addition from 150 other
children, thus providing 300 blood samples, 150 from each
randomisation group. The immunological analyses were
repeated, supplemented by analyses for specific antibody
responses to other vaccines (Diphteria, tetanus, Bordetella
pertussis, Haemophilus influenzae type b and S. pneu) and
analyses for allergic sensitisation (specific immunoglobulin
E). Stool samples were obtained from a subset of partici-
pants in the blood sample cohort. All children included at
Kolding Hospital were invited to have a blood sample drawn
for analysis for allergic sensitisation.
6.3.5. Data collection speciﬁcally for premature children
As a safety measure we followed the premature children
(born at gestational age 32 weeks + 0 days to 36 weeks
+ 6 days) more intensively. Psychomotor development at
6, 13 and 22 months after birth was assessed by means of
ASQ.
7. Sample size consideration, power calculation
At least 20% of the child population in Denmark are
hospitalised during the first year of life [21]. Sample size
estimates were based on 95%-confidence intervals and 90%
power. To detect a 20% protection against hospitalisation
during the first 15 months of life, 3972 infants needed to
be included (1986 BCG-immunised and 1986 non-BCG-
immunised). With an incidence of 5% of eczema in the child
population below 15 months of age, it was necessary to
include 4230 infants (2115 in each group) to be able to
detect a 40% protection against eczema. We therefore aimed
at including 4300 newborns. Sub-analyses on sub-groups of
participants or less frequent events may not be adequately
powered.
8. Monitoring and rules of termination
The trial was supervised by the Good Clinical Practice Units
in the Capital Region and in the Region of Southern Denmark.
The study was monitored by an independent DSMB with three
members who evaluated the study status, patterns of adverse
reactions, and the distribution of background information and
outcomes in the two groups of randomisation. The trial was to
be terminated if BCG had a significantly negative effect
(p b 0.01) or a significantly positive effect (p b 0.001) on
physician consultations as obtained through the interviews
and/or on parental report of eczema.
9. Statistical methods
Comprehensive statistical analysis plans were developed for
the primary aswell as for secondary outcomes; these planswere
deposited with the DSMB before the analyses were commenced.
Data were analysed by “intention-to-treat” and “per protocol”
and adjusted for the stratified randomisation design. The “per
protocol”-analyses excluded children, who did not follow their
randomisation groups. Thus, both children randomised to BCG-
vaccination but not BCG-vaccinated, and children randomised to
no BCG-vaccination but BCG-vaccinated outside the Calmette
Study were excluded from the “per protocol”-analyses. We
analysed outcomes in Cox proportional hazards model, so
hospitalisations occurring before the date of enrolment into the
trial were ignored. Children were followed until 15 months of
age, corresponding to the age of MMR immunisation (mumps,
measles and rubella) according to the Danish Childhood
Immunisation Program.
The possible effect of BCG was analysed overall from 0 to
15 months, but also analysed corresponding to the periods
when childhood vaccines are given during the first year of life:
at 3, 5 and 12 months of age. At these time points Danish
children are due to receive the pentavalent vaccine (against
diphtheria, tetanus, Bordetella pertussis, polio and Haemophilus
influenzae type B) and the pneumococcal conjugated vaccine
(vaccine against 13 strains of S. pneu). Hence, it is possible to
test if the potential BCG effect is modified by subsequent
vaccines. We hypothesise the effect of BCG immunisation to be
most pronounced in the first 3 months of life. The randomised
trials of BCG from West Africa [6,7] have shown that the
positive effects of BCG in boys occur already in the first week of
life while they occur later for girls (authors' unpublished
data). Thus, we tested the possible effects of BCG and their
timing separately for boys and girls. P-values less than 5%
were considered statistically significant and all tests were
two-sided.
10. Registration number
The trial was approved by the Danish Data Protection Board
(J.no. 2009-41-4141), the Committees on Biomedical Research
Ethics (J.no. H-3-2010-087), and the Danish Medicines Agency
(J.no. 2612-4356. EudraCT 2010-021979-85. Protocol 2009-
323). The study was registered at www.ClinicalTrials.gov with
trial registration number NCT01694108.
11. Economy
The study was initiated and planned by the researchers and
funded by the three involved hospitals and by the Danish
National Research Foundation (DNRF108). Supplementary
funding was granted by other non-commercial foundations.
The BCG vaccine was produced by Statens Serum Institut,
Copenhagen, Denmark, and bought by the Danish Calmette
Study. The study participants were insured by the Patient
Insurance Act. There was no remuneration for participation in
the Danish Calmette Study.
12. Steering Group
The Steering Group consists of representatives from the three
inclusion sites, from Research Centre for Vitamins and Vaccines
and from Bandim Health Project. The Steering Group is
responsible for the data and blood samples collected.
13. Discussion
During 14 months in 2012–2013 a total of 4184 families
were included in the Danish Calmette study. The crude
adherences at the clinical examination at 3 and 13 months of
age were above 93%. More than 85% completed the ASQ
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questionnaire at 13 months of age. Since the Danish health
registers are population based, the registry-based follow-up
included 100% of the study population (Fig. 1).
Collecting the main outcome data from national regis-
tries reduces the risk of bias as data were registered by
people outside the study group, independent of the
exposure.
If BCG vaccination at birth can reduce early childhood
morbidity in high-income settings, this may have significant
public health and socio-economic impact, both by improving
the quality of life for the infants and their families and by
reducing healthcare costs.
13.1. Trial status
The Danish Calmette Study is a large multicenter randomised
clinical trial in Denmarkwithmore than 4000 participants and an
adherence at 1 year follow-up ofmore than 93%. The recruitment
stoppedNovember 2013 and the clinical follow-up ended January
2015. Data from Danish health registers were obtained in 2015.
13.2. Competing interests
We declare that we have no conflict of interests.
Fig. 1. Inclusion into the Danish Calmette Study and plan for the follow-up. *1: Not all invitedwomen could be contacted in spite of at least five telephone calls or due to
the telephone number being unknownor due to lack of staff (mainly initially in the study period). *2: Some childrenwere not randomisedwithin their first 7 days of life
due to bigwork-load at thematernitywardor because the family bymistakewasdischargedbefore randomisation. Some childrenwere born at other hospitals and thus
not randomised. *3: 4105 children were born as singletons, 154 as twins, and three as triplets. Twins and triplets were randomised to the same group.
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